Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Safety, pharmacokinetic, pharmacodynamic, and efficacy da... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
0
Authors
Jeffrey Infante
•
Leslie Fecher
16 more
•
Wells Messersmith
Published
July 16, 2012
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Biochemistry
Cancer Oncology
Internal Medicine
Chemistry
Biochemistry
Medicine
Cancer Oncology
Internal Medicine
Show all topics
DOI
10.1016/s1470-2045(12)70270-x
